{"organizations": [], "uuid": "8e4e3ec74da0cbc8dcb8fca7b21bc281920e9314", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ironwood-and-allergan-announce-set/brief-ironwood-and-allergan-announce-settlement-with-aurobindo-pharma-resolving-linzess-patent-litigation-idUSFWN1SA1AE", "country": "US", "domain_rank": 408, "title": "Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-04T04:22:00.000+03:00", "replies_count": 0, "uuid": "8e4e3ec74da0cbc8dcb8fca7b21bc281920e9314"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ironwood-and-allergan-announce-set/brief-ironwood-and-allergan-announce-settlement-with-aurobindo-pharma-resolving-linzess-patent-litigation-idUSFWN1SA1AE", "ord_in_thread": 0, "title": "Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan announce settlement with aurobindo pharma resolving linzess patent litigation may", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Allergan plc:\n* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION\n* SETTLEMENT WITH AUROBINDO IS SECOND PATENT INFRINGEMENT SETTLEMENT COMPANIES HAVE REACHED WITH RESPECT TO LINZESS\n* IRONWOOD, CO TO GRANT AUROBINDO PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN UNITED STATES BEGINNING ON AUG 5, 2030\n* ALL ONGOING HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND AUROBINDO PHARMA REGARDING LINZESS PATENTS WILL BE DISMISSED\n* ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T04:22:00.000+03:00", "crawled": "2018-05-04T16:59:50.007+03:00", "highlightTitle": ""}